Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The CDC has issued increasingly urgent warnings about the possible emergence of drug-resistant strains of the STI.
In a recent trial, the investigational entry inhibitor helped fully suppress HIV in a majority of those with multidrug-resistant virus.
Researchers gave the antibody treatment to those with multidrug-resistant HIV along with an optimized antiretroviral regimen.
An ongoing study is giving the regimen to those acutely infected with HIV, before waiting for results of resistance and other lab tests.
The goal is an inexpensive point-of-care test that quickly determines an individual’s best treatment options.
Tivicay (dolutegravir) is a next-generation integrase inhibitor.
Most of such drug resistance seen is to older drugs.
In an ongoing trial of people on failing antiretroviral regimens, the injectable PRO 140 reduced viral load considerably.
The Food and Drug Administration approves antibody treatment Trogarzo for multidrug-resistant HIV.
However, two similar cases have been reported in Australia.
U.K. public health officials have expressed great concern over this latest sign of evolution of the sexually transmitted infection.
An analysis of the Seattle area HIV population sought to determine the prevalence of virus resistant to both drugs in Truvada.
After a gay man tested HIV positive, a test of his hair indicated he’d adhered well to PrEP—but did he contract a drug-resistant strain?
The intravenous medication, which should be used with standard antiretrovirals, has a wholesale acquisition cost of $118,000 per year.
One injection of the cloned antibody significantly reduced participants’ viral load in a recent advanced trial.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.